Insights

Innovative In Vivo Platforms Abintus Bio specializes in pioneering in vivo genetic medicine technologies that engineer immune cells directly within the patient’s body, offering a unique approach that could appeal to pharma and biotech partners seeking advanced cell therapy solutions.

Strong Scientific Foundation With over 20 years of prior development and $275 million invested in related technologies, Abintus possesses deep expertise and a robust pipeline, positioning it as an attractive collaborator for organizations looking to expand their gene editing and cellular therapy capabilities.

Expanding Leadership Team The recent appointment of a Head of Synthetic Biology highlights the company’s commitment to scientific excellence and innovation, signaling potential for strategic partnerships in synthetic biology and immune engineering.

Growing Funding & Recognition Backed initially by notable investors like Takeda Ventures and LLS TAP, and with substantial progress through clinical trials, Abintus is positioned for future growth, creating opportunities for investors and partners interested in cutting-edge gene therapy advancements.

Market Niche & Competitive Edge Focused on in vivo cell engineering targeting complex diseases such as leukemia, solid tumors, and autoimmune disorders, Abintus offers novel therapeutic platforms that can complement and enhance existing cell therapy pipelines of potential partner companies.

Abintus Bio, Inc. Tech Stack

Abintus Bio, Inc. uses 8 technology products and services including WordPress, Open Graph, Lightbox, and more. Explore Abintus Bio, Inc.'s tech stack below.

  • WordPress
    Content Management System
  • Open Graph
    Content Management System
  • Lightbox
    Javascript Libraries
  • Choices
    Javascript Libraries
  • Kinsta
    Platform As A Service
  • HTTP/3
    Web & Portal Technology
  • Google Analytics
    Web Analytics
  • Apache HTTP Server
    Web Servers

Abintus Bio, Inc.'s Email Address Formats

Abintus Bio, Inc. uses at least 1 format(s):
Abintus Bio, Inc. Email FormatsExamplePercentage
Last@abintusbio.comDoe@abintusbio.com
30%
Last_First@abintusbio.comDoe_John@abintusbio.com
20%
First.Last@abintusbio.comJohn.Doe@abintusbio.com
20%
Last@abintusbio.comDoe@abintusbio.com
30%

Frequently Asked Questions

Where is Abintus Bio, Inc.'s headquarters located?

Minus sign iconPlus sign icon
Abintus Bio, Inc.'s main headquarters is located at San Diego, California United States. The company has employees across 2 continents, including North AmericaAsia.

What is Abintus Bio, Inc.'s official website and social media links?

Minus sign iconPlus sign icon
Abintus Bio, Inc.'s official website is abintusbio.com and has social profiles on LinkedInCrunchbase.

What is Abintus Bio, Inc.'s SIC code NAICS code?

Minus sign iconPlus sign icon
Abintus Bio, Inc.'s SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Abintus Bio, Inc. have currently?

Minus sign iconPlus sign icon
As of March 2026, Abintus Bio, Inc. has approximately 3 employees across 2 continents, including North AmericaAsia. Key team members include Head Of Synthetic Biology: L. N.Accounting Consultant: J. F.. Explore Abintus Bio, Inc.'s employee directory with LeadIQ.

What industry does Abintus Bio, Inc. belong to?

Minus sign iconPlus sign icon
Abintus Bio, Inc. operates in the Biotechnology Research industry.

What technology does Abintus Bio, Inc. use?

Minus sign iconPlus sign icon
Abintus Bio, Inc.'s tech stack includes WordPressOpen GraphLightboxChoicesKinstaHTTP/3Google AnalyticsApache HTTP Server.

What is Abintus Bio, Inc.'s email format?

Minus sign iconPlus sign icon
Abintus Bio, Inc.'s email format typically follows the pattern of Last@abintusbio.com. Find more Abintus Bio, Inc. email formats with LeadIQ.

When was Abintus Bio, Inc. founded?

Minus sign iconPlus sign icon
Abintus Bio, Inc. was founded in 2020.

Abintus Bio, Inc.

Biotechnology ResearchCalifornia, United States2-10 Employees

Driven by a bold founding vision: Empowering patients from within, Abintus is pioneering potentially curative, off-the-shelf genetic medicines that engineer cells directly inside the patient’s body, also termed in vivo. These therapies are based on Abintus' clinically proven Modular Delivery Platform (MDP). The company’s two initial, fit-for-purpose, In Vivo programs are:
 
1. Highly selective gene expression targeting cell type/state via synthetic biology (e.g., In Vivo CAR-NK/T/Treg, In Vivo TCR-T) with applications across multiple gene delivery systems (e.g., AAV, lenti, adeno, retro) and therapeutic areas including leukemia, solid tumors, autoimmune, infectious, and genetic disease.

2. Simultaneous engineering of a diverse repertoire of active innate and adaptive immune cells (e.g., In Vivo CAR-X) with applications in diseases such as lymphoma and solid tumors.
 
Abintus is leveraging over 20 years and $275 million of prior technology advancement for in vivo engineering including the treatment of over 350 patients through Phase 3 registration trials.
 
Our company name comes from the Latin words “ab intus”, which means “from within”. We chose this name for 3 reasons: 

1)	Patients: We are pursuing product candidates that are designed to directly empower patients’ own immune cells to fight their disease from within.

2)	Science: Our team is committed to scientific excellence and continual learning. Our differentiated technologies have the potential to directly reprogram activated immune cells “in situ”, or from within.

3)	Culture: We believe our ability to achieve our vision will come from within - by building a performance-driven culture that prioritizes career development and rewards outstanding contributions.

Abintus’ initial funding syndicate included Takeda Ventures and The Leukemia & Lymphoma Society’s Therapy Acceleration Program® (LLS TAP). Abintus Bio, Inc. (“Abintus”) is headquartered in San Diego. www.abintusbio.com.

Section iconCompany Overview

Headquarters
San Diego, California United States
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2020
Employees
2-10

Section iconFunding & Financials

  • $1M

    Abintus Bio, Inc.'s revenue is estimated to be in the range of $1M

Section iconFunding & Financials

  • $1M

    Abintus Bio, Inc.'s revenue is estimated to be in the range of $1M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.